Lineage Cell Therapeutics Inc (LCTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.08-1.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LCTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 43.2% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -26.8% |
Growth built into the price is above our model estimate.
The price assumes 70.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
LCTX — earnings in line
Dated 2026-08-06
and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Progress in this program may open new markets. It could also show Lineage's manufacturing skills.
Supportive ifCOR1 is moving into models for possible clinical tests.
Worry ifDevelopment of COR1 is delayed or fails to meet internal criteria.
Why it matters: Progress in this study will show if OPC1 can treat spinal cord injuries. Success could support the therapy's path.
Supportive ifSuccessful use of OPC1 on more participants in the DOSED study is reported.
Worry ifReports of problems or slow enrollment in the study.
Why it matters: New partnerships could help Lineage grow. They may also support its cell-based therapies.
Supportive ifA partnership with a big biotech or pharma company is announced.
Worry ifNo new partnerships announced in the next quarter.
Why it matters: Adding skilled members could improve Lineage's strategy. It may also boost trust in cell therapy.
Supportive ifNew members with strong backgrounds in important areas were announced.
Worry ifNo new members were added. There is also negative feedback on the current board.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$228 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $573 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,745 loss on $10,000 · 47.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New treatment candidates are important for Lineage's growth. Progress may lead to more money.
Supportive ifA successful clinical trial or a new candidate moves to the next phase.
Worry ifNo updates on treatment candidates for two quarters in a row.
Why it matters: Success here could improve how we make future therapies.
Supportive ifThe AlloSCOPE 5D process is now working for larger production.
Worry ifThere may be failure to scale the process or big delays in development.
Why it matters: Initial data will show if the corneal cell therapy can advance to clinical trials. Positive results could signal strong potential for this new asset.
Supportive ifInitial data from the COR1 program is expected in 2026.
Worry ifNo data is available. Results are poor, which slows clinical progress.
Why it matters: Success in animal tests would show that COR1 might help treat corneal diseases.
Supportive ifEarly data from the COR1 program shows good results in animal tests.
Worry ifCOR1 program fails to show positive results in animal testing.
Why it matters: Good data would help the work with Roche and Genentech. It could raise confidence in OpRegen's market chance.
Supportive ifPositive interim results came from the Phase 2a GAlette study at 17 sites.
Worry ifNegative or unclear results came from the Phase 2a GAlette study.
Why it matters: Updates on this study could show how well the new delivery system works. Good results may boost the company's image.
Supportive ifSuccessful use of OPC1 on more participants in the DOSED study.
Worry ifThere are reports of issues in the ongoing OPC1 clinical study.
Why it matters: Progress in these projects could improve production. This may lead to savings and more output.
Supportive ifSuccessful scaling of AlloSCOPE and ILT1 projects beyond current goals.
Worry ifThere are setbacks and delays in the AlloSCOPE and ILT1 manufacturing projects.